Q1 2025 Veru Inc Earnings Call Transcript

Feb 13, 2025 / 01:00 PM GMT

Release Date Price: $5.26 (-4.45%)

Transcript 10-Q8-K

Key Points

Positve

Veru Inc (VERU) reported positive top-line results from its Phase 2B clinical study for Novosarm, showing significant preservation of lean body mass in older patients.
The company successfully sold its FC2 female condom business, allowing it to focus on its biopharmaceutical pipeline.
Veru Inc (VERU) has sufficient cash to fund operations until the end of the calendar year, providing financial stability for ongoing projects.
The company's drug development strategy includes exploring Subisobulin as a treatment for inflammation in atherosclerotic cardiovascular disease, addressing a significant unmet medical need.
Veru Inc (VERU) plans to move forward with a Phase 3 study for Novosarm, aiming for a 52-week treatment duration to capture long-term benefits.

Negative

Veru Inc (VERU) reported a net loss of $1.8 million from continuing operations, indicating ongoing financial challenges.
The sale of the FC2 female condom business resulted in a $4.2 million loss, impacting the company's financial position.
The company has a negative cash flow from operations and will need additional capital to support its drug development candidates.
There is a 13% dropout rate in the clinical study due to gastrointestinal side effects associated with GLP-1 receptor agonists.
The safety data from the Phase 2B study remains blinded, and full safety results will only be available after the extension study is completed.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VERU.OQ - Veru Inc
Q1 2025 Veru Inc Earnings Call
Feb 13, 2025 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning ladies and gentlemen, and welcome to Verru Inc.s investors conference call.

All participants will be in listen-only mode.

Should you need assistance, please signal a conference specialist by pressing the star key followed by 0.

After this morning's discussion, there will be an opportunity to ask questions.

Please note that this event is being recorded.

I would now like to turn the conference over to Mr. Sampish, Faru Incs, executive Director, Investor Relations and corporate communications. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.